Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate.
第一作者:
Ray,Fitzpatrick
第一单位:
Royal Wolverhampton Hospitals, New Cross Hospital, Wolverhampton, UK, rayfitzpatrick@nhs.net.
作者:
医学主题词
投药, 口服(Administration, Oral);抗风湿药(Antirheumatic Agents);关节炎, 类风湿(Arthritis, Rheumatoid);生物制品(Biological Products);费用效益分析(Cost-Benefit Analysis);人类(Humans);注射, 皮下(Injections, Subcutaneous);甲氨蝶呤(Methotrexate);模型, 经济学(Models, Economic);再治疗(Retreatment);治疗结果(Treatment Outcome)
DOI
10.1007/s10067-013-2318-z
PMID
23835658
发布时间
2022-03-17
- 浏览36
Clinical rheumatology
1605-12页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



